"Health News - Medicine, Diet and Fitness"

The Medicines and Healthcare products Regulatory Agency (MHRA) has forced Eli Lilly to withdraw an advice leaflet. The leaflet, providing doctors with advice on treatments for mental health, was written on behalf of Diabetes UK and carried the logo of the charity, reports the Financial Times.

However, Eli Lilly admitted that it omitted to include that it had sponsored the leaflet, calling the mistake an oversight. The firm was also criticised for not making the risk of schizophrenia medicines clear, including its own drug Zyprexa (olanzapine), to people suffering from hyperglycaemia and diabetes. The MHRA has called for Eli Lilly to withdraw the information, originally distributed in 2003, although it was removed in May last year by the firm.

While California Moves Forward, Bush Pushes Back on Health Care
Statement of CALPIRG Health Care Advocate Emily Clayton on President Bush’s planned health care proposals for the State of the Union

“Just as California and other states are preparing to take big steps forward on the path to better regulating the health insurance industry and expanding health care coverage, President Bush is set to propose some giant steps back in his State of the Union address tonight.

(more…)

If you’re new here, you may want to subscribe to my RSS feed.Thanks for visiting!

www.drweil.com/drw/u -

Tips for Reliving Arthritis Pain Using Natural Remedies
Another alternative is to use a natural remedy as an alternative to medications. … My List of Beneficial Foods and Supplements for Rheumatoid Arthritis …

Natural approach to Arthritis
(more…)

Forest Laboratories has decided to up figures for research and development (R&D) spending. The move comes as a way to include new agreements with US firms Mylan Laboratories and Replidyne.

Forest made an upfront payment to Mylan of $50 million under an agreement for the commercialization, development and distribution of the beta blocker nebivolol in the US and Canada. This was followed by a similar deal worth $50 million for Replidyne’s oral antibiotic faropenem medoxomil.
(more…)

Eli Lilly is to buy back worldwide marketing rights for Yentreve/AriClaim (duloxetine hydrochloride) from Boehringer Ingelheim. As a stress urinary incontinence (SUI) treatment, along with future related urinary incontinence indications, the drug will continue to be marketed outside the US by Lilly but other treatments using duloxetine will remain under both firms.

Lilly president and chief operating officer John Lechleiter said: “Based on our collective experiences to date in the marketplace, both companies believe that the Yentreve/AriClaim opportunity is best suited and can be best commercialised in markets outside the US with the support of one company. “This is about ‘right sizing’ our investments to address our greatest opportunities and the greatest patient needs.” Dr Alessandro Banchi, Boehringer Ingelheim chairman of the board of managing directors, added: “There has been an excellent spirit of collaboration in our alliance with Lilly.
(more…)

Senate to follow

The House today passed significant reforms to the Food and Drug Administration’s drug safety review system. Part of a comprehensive FDA bill, the bill was a compromise between Senate and House legislation that passed overwhelmingly earlier this year. The bill, which includes strong consumer protections, will be voted on in the Senate tomorrow.

Statement by CALPIRG’s Federal Health Care Advocate Paul Brown:

(more…)

Washington — The American College of Physicians has endorsed the concept of a single-payer health care system for the first time.

In a new position paper, the organization, which represents 124,000 physicians in internal medicine and related subspecialties, identified a system in which the federal government is the sole third-party payer as one of two reform vehicles to achieve universal coverage. The other is a public-private system that includes a legal guarantee that everyone has access to coverage and that offers health care subsidies to low-income residents.

(more…)

GPs are more likely to prescribe headache drugs to middle-aged women than men, a study has claimed. Researchers at King’s College London found women aged between 45 and 54 were three times as likely to visit their GP about headaches while men were more likely to be referred to hospital.

Prescribing was most common for women aged 45 to 54, who were given 78 prescriptions for every 100 consultations. They also found one in three women were given migraine drugs compared to one in four men, while women aged 15 to 24 were the group most likely to see their GP about headaches. In a study of 253 GP practices over a nine-year period, it was found women’s consultation rate for headaches was 6.4 out of every 100 per year compared to 2.5 for men. Headaches are the most common neurological symptom seen by neurologists and family doctors. They also rank among the top ten reasons for consulting a doctor and account for 20 per cent of sick leave taken by workers.
(more…)

Don’t wait for the holidays!
Click here to order “Your Baby” DVD through PayPal:
 

(Ivanhoe Newswire) — Studies show up to 20 percent of a child’s IQ is influenced by prenatal and postnatal experience. Learn what you and your baby need before and after birth with these 15 compelling news reports produced by the leading medical news reporting team in the country:

1. Brainy Babies
2. Easier Pregnancies
(more…)

STANFORD, Calif. - The drug most commonly used to arrest preterm labor, magnesium sulfate, is more likely than another common treatment to cause mild to serious side effects in pregnant women, according to a study from researchers at Lucile Packard Children’s Hospital and Stanford University School of Medicine.

Their findings suggest that, since the effectiveness of the two drugs appears similar, physicians should consider side effects more strongly when choosing which drug to prescribe.

(more…)